AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25913046
Drug: Both isotonic
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both isotonic and hypotonic solutions
Trial: 20653455
Drug: Both medications
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both medications at bedtime (valsartan 160 mg/day and amlodipine 5 mg/day)
Trial: 20653455
Drug: Both medications
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both medications on awakening (valsartan 160 mg/day and amlodipine 5 mg/day)
Trial: 16997056
Drug: Gentamicin/citrate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin/citrate (4 mg/mL)
Trial: 9541997
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of food components and toxic compounds
Trial: 8173923
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 3 micrograms kg‐1 min‐1 for 48 hours after surgery
Trial: 8173923
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 3 litres 5% dextrose and bolus of intravenous frusemide 1 mg kg‐1
Trial: 28833428
Drug: Feedback reports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback reports containing information in combination with response certitude
Trial: 25625938
Drug: D3P (docetaxel:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3P (docetaxel: 75 mg/m2, intravenous infusion, every three weeks; Prednisone 10mg orally daily)
Trial: 25625938
Drug: M3P (mitoxantrone:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M3P (mitoxantrone: 12 mg/m2, intravenous infusion, every three weeks; Prednisone 10mg orally daily)
Trial: 1396621
Drug: Tetracycline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (250 mg for children, 500 mg for adults)
Trial: 3530366
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant treatment (Control)
Trial: 3530366
Drug: Coumarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumarin treatment (in limb salvage surgery)
Trial: 3530366
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant treatment (Control, in limb salvage surgery)
Trial: 14637276
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment for 12 weeks
Trial: 24047007
Drug: Intranasal pack
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal pack (Group B)
Trial: 12697487
Drug: Itraconazole treatment
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole treatment group
Trial: 10432616
Drug: Ethanol consumption
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol consumption (approximately 0.3 g/kg) as beer, white wine, or vodka mixed with orange juice
Trial: 8520505
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) and total body irradiation (TBI) followed with autologous blood stem cell transplantation (ABSCT)
Trial: 1722692
Drug: Mu‐cron tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mu‐cron tablets (phenylpropanolamine 50 mg)
Trial: 1722692
Drug: Boots Cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boots Cold Relief tablets (phenylephrine 10 mg and caffeine 60 mg)
Trial: 1722692
Drug: Boots Pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boots Pain Relief tablets (caffeine 60 mg)
Trial: 6460717
Drug: Imipramine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine at 75 mg/day
Trial: 6460717
Drug: Zimelidine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine at 100 mg/day
Trial: 6460717
Drug: Zimelidine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine at 200 mg/day
Trial: 6460717
Drug: Imipramine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine at 25 mg three times daily
Trial: 19537838
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 or 120 mg/day
Trial: 22545079
Drug: Routine 12-weekly
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine 12-weekly CD4 monitoring from year 2 on ART
Trial: 9667165
Drug: Desensitizing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing agents (specific agents not detailed)
Trial: 2671289
Drug: Carboplatin (CBDCA)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBDCA) plus Methotrexate (MTX) - CBDCA administered IV monthly at doses of 400 mg/m2, MTX given IV weekly at doses of 40 mg/m2.
Trial: 2671289
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) alone - administered IV weekly at doses of 40 mg/m2.
Trial: 335903
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (intravenous administration)
Trial: 25694417
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib (LAP) 1500mg monotherapy on days 1-21
Trial: 20128352
Drug: Group MAP
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group MAP (antimalarial, retinol supplement, and anti-parasitic drug)
Trial: 20128352
Drug: Group MA
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group MA (antimalarial and retinol supplement)
Trial: 20128352
Drug: Group MP
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group MP (antimalarial and anti-parasitic drug)
Trial: 20128352
Drug: Group M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group M (treatment only with antimalarials)
Trial: 12723459
Drug: Intravenous dichloroacetate
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dichloroacetate (DCA) 50 mg/kg
Trial: 10757193
Drug: Oxandrolone 20
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone 20 mg/day
Trial: 10757193
Drug: Placebo 20
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20 mg/day
Trial: 8486815
Drug: Ethanol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (1.0 g/kg)
Trial: 27462009
Drug: SMC021 (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC021 (0.8 mg/d)
Trial: 22677763
Drug: Cereton (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereton (4 ml, 1000 mg intravenously for 10 days) in combination with traditional treatment
Trial: 26406216
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment only
Trial: 20453679
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH), 0.075 mg x kg(‐1) x day(‐1)
Trial: 17506156
Drug: Nicotine +
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine + 6 mg mecamylamine
Trial: 17506156
Drug: Nicotine +
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine + 3 mg mecamylamine
Trial: 6340153
Drug: Glucagon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (1 mg I.V.)
Trial: 15614570
Drug: Otovowen (alternative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otovowen (alternative treatment)
Trial: 7503204
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 800 micrograms administered 3 days after methotrexate 50 mg/m2 intramuscularly (group 1)
Trial: 7503204
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 800 micrograms administered 7 days after methotrexate 50 mg/m2 intramuscularly (group 2)
Trial: 7503204
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to human chorionic gonadotropin-beta level < or = 25 IU/L in group 1
Trial: 7503204
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to human chorionic gonadotropin-beta level < or = 25 IU/L in group 2
Trial: 7503204
Drug: Treatment failures
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment failures in group 1
Trial: 7503204
Drug: Treatment failure
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment failure in group 2
Trial: 2188753
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g methylprednisolone (steroid) infused intravenously 2‐24 hours before planned PTCA
Trial: 6792956
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (cromolyn) 40 mg
Trial: 22244840
Drug: PDL +
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PDL + imiquimod 5% cream
Trial: 17803845
Drug: Terazosin 2
RxNorm normalized name: terazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin 2 mg once daily for six weeks
Trial: 17803845
Drug: Terazosin 2
RxNorm normalized name: terazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin 2 mg once daily and tolterodine 2 mg twice daily for six weeks
Trial: 15280079
Drug: ACh (Acetylcholine)
RxNorm normalized name: By Ache
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACh (Acetylcholine) delivered via intradermal microdialysis
Trial: 15280079
Drug: L-NAME (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (5 mM) delivered simultaneously via the dialysis probe
Trial: 15280079
Drug: H1 receptor
RxNorm normalized name: Histamine H1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 receptor antagonist levocetirizine
Trial: 24565713
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 400 μg once daily (QD) in the evening
Trial: 24565713
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium (ML) 10 mg QD pm
Trial: 24565713
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 200 μg QD pm
Trial: 24565713
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 250 μg twice daily
Trial: 22334769
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 400 μg
Trial: 10450447
Drug: Amodiaquine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (35 mg/kg)
Trial: 10450447
Drug: Sulfadoxine-pyrimethamine (sulfadoxine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (sulfadoxine, 25 mg/kg)
Trial: 2193477
Drug: Methicillin antibiotic
RxNorm normalized name: methicillin
DrugBank: Meticillin (DB01603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methicillin antibiotic prophylaxis
Trial: 31961446
Drug: methyl aminolaevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Trial: 25527482
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor physical therapy (PT)
Trial: 25527482
Drug: Levator-directed trigger-point
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levator-directed trigger-point injections (LTPI)
Trial: 15213034
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 16 mg.kg(‐1).d(‐1)
Trial: 15213034
Drug: Methionine intakes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intakes of 3, 6, 9, 13, 18, 21, and 24 mg.kg(‐1).d(‐1)
Trial: 15213034
Drug: 24‐h [(13)C]leucine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24‐h [(13)C]leucine tracer infusion
Trial: 11694786
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of Herceptin (4 mg/kg initial dose followed by 2 mg/kg i.v. weekly)
Trial: 11694786
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of Herceptin (8 mg/kg initial dose followed by 4 mg/kg i.v. weekly)
Trial: 11694786
Drug: Herceptin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin (both doses)
Trial: 8065591
Drug: Dihydrogesterone with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrogesterone with transdermal estradiol
Trial: 8065591
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate with transdermal estradiol
Trial: 3389318
Drug: Diets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diets containing averages of 1.22‐1.67 mg/d vitamin B‐6; actual mean vitamin B‐6 content analyzed was 0.75‐0.98 mg/d.
Trial: 3389318
Drug: Diets analyzed
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diets analyzed to contain means of 0.75‐0.98 mg/d of vitamin B-6.
Trial: 29461420
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg) administered 15 minutes before the race and again after 5 hours if the route was not completed
Trial: 29461420
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ibuprofen)
Trial: 25766309
Drug: Intensive, multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive, multimodal phonologic therapy (60 hours)
Trial: 20644965
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (two 30‐min classical massages per week for 5 weeks)
Trial: 19929995
Drug: Taspoglutide 8
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 8 mg
Trial: 19929995
Drug: Taspoglutide 30
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 30 mg
Trial: 11212045
Drug: Nicorandil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (0.1 mg/kg bolus followed by infusion at 1 microg x kg(-1) x min(-1))
Trial: 9877016
Drug: Sumatriptan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (100 mg PO)
Trial: 3288293
Drug: Indomethacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (single 50 mg dose)
Trial: 3288293
Drug: Indomethacin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (multiple doses of 25 and 50 mg tid for 5 days)
Trial: 8383904
Drug: Propranolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1 mg.min‐1 for 5 min followed by 0.1 mg.min‐1 for 115 min)
Trial: 8383904
Drug: Propranolol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol + Isoproterenol (infused between 30 and 90 min of propranolol infusion)
Trial: 2946509
Drug: Specific thromboxane
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific thromboxane synthetase inhibitor, UK-38,485
Trial: 31063434
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of 120 g of cooked Moringa oleifera leaves
Trial: 26576858
Drug: Betahistine 18
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 18 mg plus ondansetron 4 mg
Trial: 26576858
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg alone (placebo group)
Trial: 20517680
Drug: Platelet-derived growth
RxNorm normalized name: Platelet-derived growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-derived growth factors (platelet-leukocyte gel)
Trial: 10918098
Drug: Prochlorperazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (10 mg intravenously)
Trial: 21572992
Drug: Promethazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (25 mg intravenously)
Trial: 3886303
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tiaprofenic acid 3-times daily
Trial: 24628859
Drug: Patients reporting
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients reporting monthly angina (n=188)
Trial: 24628859
Drug: Patients reporting
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients reporting weekly angina (n=283)
Trial: 24628859
Drug: Patients reporting
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients reporting daily angina (n=49)
Trial: 15901241
Drug: Nicorandil (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (an agonist of KATP channels)
Trial: 15901241
Drug: IP pretreated
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP pretreated with glibenclamide (an antagonist of KATP channels)
Trial: 9882035
Drug: Leeds Dyspepsia
RxNorm normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leeds Dyspepsia Questionnaire (LDQ) administered to patients with dyspepsia
Trial: 9882035
Drug: Leeds Dyspepsia
RxNorm normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leeds Dyspepsia Questionnaire (LDQ) before and after therapy
Trial: 7927617
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (Engerix B-10 microgram each) at 0, 6 and 14 weeks (group A)
Trial: 7927617
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (Engerix B-10 microgram each) at 0, 1 and 2 months (group B)
Trial: 3286327
Drug: rDNA human
RxNorm normalized name: INSULIN,ULTRALENTE,HUMAN/rDNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rDNA human insulin (HI)
Trial: 20733014
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-treatment)
Trial: 24228531
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine combined HAART
Trial: 21642064
Drug: Robot-assisted gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted gait training (RAGT) combined with conventional physical therapy (24 1-hour sessions)
Trial: 21642064
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (24 1-hour sessions)
Trial: 19564366
Drug: Artemether-lumefantrine (80/480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (80/480 mg) twice daily for 3 days
Trial: 19564366
Drug: Predictive modeling
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive modeling suggests a twice-daily regimen for 5 days would be preferable in later pregnancy
Trial: 8280547
Drug: rectal pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rectal pethidine
Trial: 6695297
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg diazoxide
Trial: 6695297
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg diazoxide
Trial: 6695297
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg diazoxide